No record found
* Returns not adjusted for payouts
Company Profile
Highnoon Laboratories Limited (“the Company”) was incorporated in Pakistan under the repealed Companies Ordinance 1984 (now Companies Act, 2017) (“the Act”) and its shares are quoted on Pakistan Stock Exchange since November 1994. The Company is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and related consumer products. The registered office of the Company is situated at 17.5 km, Multan Road, Lahore.
Dr. Adeel Abbas Haideri | CEO |
Tausif Ahmad Khan | Chairperson |
Mahnoor Ather | Company Secretary |
Corplink (Pvt.) Ltd. Wings Arcade, 1-K Commercial, Model Town, Lahore.
M/s EY Ford Rhodes Chartered Accountants
December
Equity Profile
Announcements
Date | Title | Document |
---|---|---|
Apr 9, 2024 | Transmission of Annual Report for the year ended 31 December 2023 | View PDF |
Mar 29, 2024 | Financial Results for the year ended 31 December 2023 | View PDF |
Oct 30, 2023 | Transmission of Quarterly Report for the period ended 30 September 2023 | View PDF |
Oct 30, 2023 | Financial Results for the Quarter ended 30 September 2023 | View PDF |
Sep 4, 2023 | Tranmission of Quarterly Report for the period ended 30 June 2023 | View PDF |
Aug 17, 2023 | Financial Results for the Quarter ended 30 June 2023 | View PDF |
Aug 15, 2023 | Financial Results for the Half Year ended on 30 June 2023 REVOKED | View PDF |
May 2, 2023 | Transmission of Quarterly Report for the period ended 31 March 2023 | View PDF |
May 2, 2023 | Financial Results for the Quarter ended 31 March 2023 | View PDF |
Apr 7, 2023 | Transmission of Annual Report for the year ended 31 December 2022 | View PDF |
Date | Title | Document |
---|---|---|
Apr 23, 2024 | Board Meeting | View |
Apr 8, 2024 | Notice of Annual General Meeting | View PDF |
Mar 28, 2024 | Board Meeting in Progress | View |
Mar 21, 2024 | Board Meeting | View |
Jan 9, 2024 | Board Meeting other than Financial Results | View |
Oct 23, 2023 | Board Meeting | View |
Aug 7, 2023 | Board Meeting | View |
Jun 12, 2023 | Extract of Resolution passed at the Board of Directors Meeting | View PDF |
Jun 9, 2023 | Board Meeting in Progress | View |
Jun 7, 2023 | Emergent Board Meeting | View PDF |
Apr 19, 2023 | Board Meeting | View |
Date | Title | Document |
---|---|---|
Apr 26, 2024 | Corporate Briefing Session Presentation | View PDF |
Apr 23, 2024 | Corporate Briefing Session | View PDF |
Feb 23, 2024 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Feb 21, 2024 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Feb 20, 2024 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Feb 14, 2024 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Jan 17, 2024 | Approval of Budget and Annual Capital for the Financial Year 2024 | View |
Aug 31, 2023 | Half Year Report 2023 | View |
Aug 17, 2023 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Aug 15, 2023 | Material Information | View PDF |
Jun 27, 2023 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Jun 26, 2023 | Credit of Bonus Share Certificates | View |
Financials
All numbers in thousands (000's) except EPS
2023 | 2022 | 2021 | 2020 | |
---|---|---|---|---|
Sales | 19,424,255 | 15,815,937 | 13,000,780 | 10,697,634 |
Profit after Taxation | 2,403,014 | 2,417,172 | 1,808,033 | 1,420,736 |
EPS | 45.35 | 45.62 | 43.17 | 41.04 |
Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | |
---|---|---|---|---|
Sales | 5,080,714 | 4,942,469 | 4,872,781 | 4,191,865 |
Profit after Taxation | 618,772 | 576,117 | 625,508 | 661,814 |
EPS | 11.68 | 10.87 | 14.93 | 12.49 |
Ratios
2023 | 2022 | 2021 | 2020 | |
---|---|---|---|---|
Gross Profit Margin (%) | 47.64 | 50.77 | 49.35 | 47.87 |
Net Profit Margin (%) | 12.37 | 15.28 | 13.91 | 13.28 |
EPS Growth (%) | (0.59) | 5.68 | 5.19 | 46.31 |
PEG | (18.80) | 2.09 | 2.80 | 0.32 |
Payouts
Date | Financial Results | Details | Book Closure |
---|---|---|---|
March 29, 2024 11:53 AM | 31/12/2023(YR) | 300%(F) (D) | 22/04/2024 - 29/04/2024 |
June 12, 2023 2:59 PM | - | 15%(I) (B) | 20/06/2023 - 22/06/2023 |
February 23, 2023 2:48 PM | 31/12/2022(YR) | 200%(F) (D) - 10% (B) | 22/04/2023 - 29/04/2023 |
March 16, 2022 3:48 PM | 31/12/2021(YR) | 200% (D) - 10% (B) | 11/04/2022 - 18/04/2022 |
March 25, 2021 4:01 PM | 31/12/2020(YR) | 150%(F) (D) - 10% (B) | 26/04/2021 - 27/04/2021 |
March 31, 2020 3:12 PM | 31/12/2019(YR) | 130% (D) - 10% (B) | 05/05/2020 - 12/05/2020 |
March 29, 2019 4:20 PM | 31/12/2018(YR) | 130%(F) (D) - 10% (B) | 23/04/2019 - 29/04/2019 |
March 9, 2018 3:55 PM | 31/12/2017(YR) | 100% (D) - 12% (B) | 12/04/2018 - 23/04/2018 |
March 16, 2017 3:45 PM | 31/12/2016(YR) | 85% (D) - 12% (B) | 21/04/2017 - 27/04/2017 |
March 15, 2016 3:38 PM | 31/12/2015(YR) | 75% (D) - 12% (B) | 14/04/2016 - 22/04/2016 |